There's a new player on the antibody-drug conjugate (ADC) scene. UK-based Pheon Therapeutics has entered stage right with $68 million in funding that will be used to fund development of a pipeline of ...
Shift verification effort from a single, time-consuming flat run to a more efficient, distributed, and scalable process.
Roche's Genentech division has formed an R&D partnership with Arsenal Biosciences focusing on developing and refining the biotech's programmable T cell-based therapies platform. Genentech is providing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback